Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.0951 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	0.0951
Bid (Size)	0.1167 (1)
Ask (Size)	0.1200 (461)
Prev. Close	0.0951
Today's Range	0.0951 - 0.0951
52wk Range	0.0951 - 33.46
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

February 17, 2026

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

February 04, 2026

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

Performance

YTD	N/A	N/A
1 Month	N/A	N/A
3 Month	N/A	N/A
6 Month	-98.8%	-98.8%
1 Year	-99.7%	-99.7%

More News

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

January 07, 2026

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened ↗

September 05, 2025

Via Stocktwits

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

December 17, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Announces Trading on OTCQB Market

December 02, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

November 05, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

November 04, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Announces Listing on OTC Markets

November 03, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's after-hours session. ↗

October 31, 2025

Via Chartmill

Top movers in Thursday's after hours session ↗

October 30, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 30, 2025

Via Benzinga

Nasdaq Falls Over 1%; Alphabet Posts Upbeat Earnings ↗

October 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 30, 2025

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗

October 30, 2025

Via Benzinga

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

October 29, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

October 21, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

October 15, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

October 13, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

September 22, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗

September 09, 2025

Via Benzinga

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

September 09, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

The trading volume of these stocks is deviating from the norm in today's session. ↗

September 08, 2025

Via Chartmill

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

September 08, 2025

From CERo Therapeutics Holdings, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is CERo Therapeutics Holdings, Inc. - Common Stock publicly traded?

Yes, CERo Therapeutics Holdings, Inc. - Common Stock is publicly traded.

What exchange does CERo Therapeutics Holdings, Inc. - Common Stock trade on?

CERo Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock?

The ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock is CERO on the Nasdaq Stock Market

What is the current price of CERo Therapeutics Holdings, Inc. - Common Stock?

The current price of CERo Therapeutics Holdings, Inc. - Common Stock is 0.0951

When was CERo Therapeutics Holdings, Inc. - Common Stock last traded?

The last trade of CERo Therapeutics Holdings, Inc. - Common Stock was at 10/30/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.